#USA #New Orleans #28bio #Neuroinflammation #CNS-3D

28bio's Groundbreaking CNS-3D Inflammatory Organoids

Introduction

On May 19, 2026, 28bio made waves in the biotechnological landscape with the launch of their CNS-3D Inflammatory Organoids. This innovative technology aims to transform how researchers evaluate the effectiveness of anti-inflammatory drugs by simulating complex human neuroinflammatory conditions within a lab environment.

Why CNS-3D Inflammatory Organoids Are Game-Changing

One of the significant challenges in neurological drug development is the high failure rate associated with anti-inflammatory therapies. This issue stems largely from the limitations of conventional animal models and 2D cell cultures, which fail to accurately mimic human neuroimmune interactions. The CNS-3D Inflammatory Organoids represent a breakthrough as they are the only commercially available 3D brain organoid model that incorporates not only neurons and astrocytes but also microglia – the immune cells of the brain. This triad allows for enhanced evaluation of inflammation-driven neural injuries and the therapeutic response of anti-inflammatory drugs.

Understanding Neuroinflammation

Neuroinflammation plays a pivotal role in the progression of various neurodegenerative diseases. Historically, it has been one of the least translatable areas of research due to the inadequacy of existing models. According to Christopher Butt, PhD, Vice President of Technology at 28bio, “For the first time, researchers can simultaneously measure inflammatory signaling, cellular responses, tissue injuries, and functional disruptions of neural networks within the same biological context.” This capability marks a significant leap forward in neuroscience research.

Key Features of CNS-3D Inflammatory Organoids

The CNS-3D Inflammatory Organoids model human neuroinflammation by using pro-inflammatory stimuli such as TNF-α, LPS, and IL-6. This cutting-edge model allows for:

• - Functional Calcium Imaging: Researchers can visualize neuronal activity in real-time while assessing the effects of anti-inflammatory treatments.
• - Cytokine Analysis: Understanding the biochemical responses occurring within the organoids enhances insights into therapeutic efficacy.
• - Multidimensional Insights: A combination of immunostaining, cytotoxicity assays, and molecular profiling provides a comprehensive view of neuroimmune biology.

Availability and Future Prospects

Starting in the third quarter of 2026, CNS-3D Inflammatory Organoids will be available in various assay-ready formats, including 24-, 48-, 96-, and 384-replicate formats. This flexibility is designed to accommodate the diverse needs of research laboratories worldwide. Stuart Gibb, Head of Business Development at 28bio, stated, “Researchers now have a more predictive model to evaluate neuroimmune biology and anti-inflammatory therapeutics.”

Additionally, this launch continues 28bio's commitment to creating a suite of comprehensive, human-relevant assays aimed at modeling disease pathogenesis and recovery in neurodegenerative conditions. Their previous introduction of CNS-3D Myelinated Organoids laid the foundation for this next phase, creating a synergy in research capabilities that could accelerate the development of effective treatments.

About 28bio

28bio is a pioneering neurotechnology company dedicated to engineering human brains at scale, focusing on functions such as memory, learning, and cognition. Utilizing their Nexon™ platform, they aim to reverse the current neurological health crisis by enhancing predictive capabilities concerning the efficacy of various therapies on humans. The company's commitment to ethical standards in the development of brain organoid technology is fundamental to their mission.

For more information on CNS-3D Inflammatory Organoids and other innovative products from 28bio, please visit their official website.